See more : China Nonferrous Mining Corporation Limited (1258.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genomma Lab Internacional, S.A.B. de C.V., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Wei Long Grape Wine Co., Ltd. (603779.SS) Income Statement Analysis – Financial Results
- Capri Holdings Limited (CPRI) Income Statement Analysis – Financial Results
- National CineMedia, Inc. (NCMI) Income Statement Analysis – Financial Results
- Sunfly Intelligent Technology Co., LTD (300423.SZ) Income Statement Analysis – Financial Results
- Syncomm Technology Corp. (3150.TW) Income Statement Analysis – Financial Results
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.genommalab.com
About Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 969.48M | 862.36M | 754.10M | 696.10M | 673.21M | 598.89M | 617.33M | 549.30M | 639.36M |
| Cost of Revenue | 375.96M | 341.27M | 288.44M | 265.09M | 251.92M | 208.74M | 205.82M | 180.53M | 225.54M |
| Gross Profit | 593.52M | 521.09M | 465.65M | 431.01M | 421.29M | 390.15M | 411.52M | 368.77M | 413.82M |
| Gross Profit Ratio | 61.22% | 60.43% | 61.75% | 61.92% | 62.58% | 65.15% | 66.66% | 67.13% | 64.72% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.84B | 6.92B | 6.57B | 5.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -6.43B | -6.57B | -6.25B | -5.38B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 404.67M | 354.91M | 319.92M | 284.36M | 300.86M | 279.11M | 283.80M | 359.55M | 417.80M |
| Other Expenses | 420.19K | 3.17M | 192.92K | 588.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 404.67M | 351.74M | 319.73M | 283.77M | 300.86M | 279.11M | 283.80M | 359.55M | 417.80M |
| Cost & Expenses | 780.52M | 693.01M | 608.17M | 548.86M | 552.77M | 487.85M | 489.62M | 540.08M | 643.34M |
| Interest Income | 156.93M | 6.05M | 3.19M | 1.58M | 1.52M | 1.61M | 2.05M | 1.61M | 1.19M |
| Interest Expense | 829.90M | 26.95M | 21.64M | 23.14M | 32.13M | 28.16M | 24.71M | 16.02M | 22.73M |
| Depreciation & Amortization | 13.38M | 11.64M | 8.29M | 7.98M | 7.53M | 4.12M | 3.57M | 4.07M | 6.85M |
| EBITDA | 166.99M | 180.99M | 142.52M | 155.22M | 118.10M | 118.57M | 131.28M | -56.82M | -943.89M |
| EBITDA Ratio | 17.23% | 20.99% | 20.45% | 22.30% | 19.01% | 19.23% | 21.27% | 2.42% | 0.45% |
| Operating Income | 188.96M | 169.35M | 145.92M | 147.24M | 120.44M | 111.04M | 127.72M | 9.22M | -3.98M |
| Operating Income Ratio | 19.49% | 19.64% | 19.35% | 21.15% | 17.89% | 18.54% | 20.69% | 1.68% | -0.62% |
| Total Other Income/Expenses | 1.53B | -54.81M | -33.33M | -38.29M | -44.83M | -30.82M | -20.76M | 3.52M | -28.32M |
| Income Before Tax | 1.72B | 114.54M | 112.59M | 108.95M | 78.44M | 86.28M | 107.99M | -76.90M | -84.92M |
| Income Before Tax Ratio | 177.48% | 13.28% | 14.93% | 15.65% | 11.65% | 14.41% | 17.49% | -14.00% | -13.28% |
| Income Tax Expense | 635.67M | 44.48M | 44.50M | 38.49M | 42.14M | 33.21M | 38.78M | 6.14M | -21.65M |
| Net Income | 63.89M | 71.22M | 63.68M | 70.44M | 40.48M | 56.34M | 65.38M | -81.59M | -61.87M |
| Net Income Ratio | 6.59% | 8.26% | 8.44% | 10.12% | 6.01% | 9.41% | 10.59% | -14.85% | -9.68% |
| EPS | 0.07 | 0.07 | 0.06 | 0.07 | 0.04 | 0.06 | 0.07 | -0.08 | -0.06 |
| EPS Diluted | 0.07 | 0.07 | 0.06 | 0.07 | 0.04 | 0.06 | 0.07 | -0.08 | -0.06 |
| Weighted Avg Shares Out | 957.34M | 993.23M | 1.01B | 1.01B | 1.01B | 1.02B | 952.49M | 980.81M | 1.03B |
| Weighted Avg Shares Out (Dil) | 957.34M | 993.23M | 1.01B | 1.01B | 1.01B | 1.02B | 952.49M | 980.81M | 1.03B |
GENOMMA LAB MANUFACTURING FACILITY GRANTED COFEPRIS OPERATING LICENSE FOR ALL ITS PHARMA / OTC MANUFACTURING LINES
Genomma Lab Internacional Reports Second Quarter 2023 Results
Genomma Lab Announces Second Quarter 2023 Financial Results Call and Webcast
Source: https://incomestatements.info
Category: Stock Reports